ATE130032T1 - Verfahren zum verringern der toxizität von lps und verfahren zum dezoxifizieren eines lps- haltigen flüssigen therapeutischen mittels. - Google Patents

Verfahren zum verringern der toxizität von lps und verfahren zum dezoxifizieren eines lps- haltigen flüssigen therapeutischen mittels.

Info

Publication number
ATE130032T1
ATE130032T1 AT87903949T AT87903949T ATE130032T1 AT E130032 T1 ATE130032 T1 AT E130032T1 AT 87903949 T AT87903949 T AT 87903949T AT 87903949 T AT87903949 T AT 87903949T AT E130032 T1 ATE130032 T1 AT E130032T1
Authority
AT
Austria
Prior art keywords
lps
fatty acids
gram
negative bacterial
acyloxyacyl hydrolase
Prior art date
Application number
AT87903949T
Other languages
English (en)
Inventor
Robert S Munford
Catherine L Hall
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE130032T1 publication Critical patent/ATE130032T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
AT87903949T 1986-05-28 1987-05-27 Verfahren zum verringern der toxizität von lps und verfahren zum dezoxifizieren eines lps- haltigen flüssigen therapeutischen mittels. ATE130032T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/868,428 US4929604A (en) 1986-05-28 1986-05-28 Lipopolysaccharides of reduced toxicity and the production thereof
US5304487A 1987-05-22 1987-05-22

Publications (1)

Publication Number Publication Date
ATE130032T1 true ATE130032T1 (de) 1995-11-15

Family

ID=26731375

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87903949T ATE130032T1 (de) 1986-05-28 1987-05-27 Verfahren zum verringern der toxizität von lps und verfahren zum dezoxifizieren eines lps- haltigen flüssigen therapeutischen mittels.

Country Status (8)

Country Link
US (3) US4929604A (de)
EP (1) EP0306496B1 (de)
JP (1) JPH04504349A (de)
AT (1) ATE130032T1 (de)
AU (1) AU610509B2 (de)
DE (1) DE3751588T2 (de)
FI (1) FI95599C (de)
WO (1) WO1987007297A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597573A (en) * 1989-05-04 1997-01-28 Igen, Inc. Lipid-A analogs: new monosaccharide and disaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities
FR2648350B1 (fr) * 1989-06-20 1994-07-01 Roussel Uclaf Utilisation de lipopolysaccharides extraits de bacteries gram(-) pour la fabrication d'un medicament facilitant la cicatrisation de la peau
JPH04270965A (ja) * 1990-05-18 1992-09-28 Burton W Blais オリゴペプタイド吸着担体の調製方法、及びこれを使用したリポ多糖類の検定と除去方法
US5281583A (en) * 1990-08-20 1994-01-25 Den'ichi Mizuno LPS-containing analgesics and veterinary analgesics
US5281520A (en) * 1990-09-12 1994-01-25 Zymogenetics, Inc. Method for producing acyloxyacyl hydrolase
US5593969A (en) * 1991-09-03 1997-01-14 Igen Incorporated Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors
US5530113A (en) * 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
AU660325B2 (en) * 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
US5824310A (en) * 1991-10-22 1998-10-20 The United States Of America As Represented By The Department Of Health And Human Services Lipopplysaccharide conjugate vaccines
IL105131A (en) * 1992-03-27 2000-06-01 Igen Inc Compounds and compositions containing such compounds comprising lipid-A analogs for eliciting therapeutic antibodies
US5439819A (en) * 1993-08-27 1995-08-08 The Regents Of The University Of California Chimeric protein tyrosine kinases
US5840302A (en) * 1993-11-10 1998-11-24 Bristol-Myers Squibb Company Treatment of bacterially-induced inflammatory diseases
US5648343A (en) * 1994-02-28 1997-07-15 The University Of Georgia Research Foundation Method for treating LPS-mediated disorders
ATE173634T1 (de) * 1994-04-20 1998-12-15 Us Army Impfstoff gegen gram-negative bakterielle infektionen
US6887483B2 (en) * 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
US6685949B1 (en) * 1998-01-13 2004-02-03 The United States Of America As Represented By The Department Of Health & Human Services Lipooligosaccharide based vaccine for prevention of moraxella (branhamella)catarrhalis infections in humans
US6207157B1 (en) * 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6172220B1 (en) 1997-01-21 2001-01-09 Board Of Regents Of University Of Nebraska Isolated algal lipopolysaccharides and use of same to inhibit endotoxin-initiated sepsis
US6444654B1 (en) 1997-01-21 2002-09-03 Board Of Regents Of University Of Nebraska Isolated asgal lipopolysaccharides and use of same to inhibit innate immune response
CA2295440A1 (en) * 1997-06-18 1998-12-23 The Rockefeller University Methods for identifying antibodies and peptides useful in the treatment of septic shock and experimental arthritis and uses thereof
US6645503B1 (en) * 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
WO2001025254A2 (en) * 1999-10-04 2001-04-12 University Of Maryland Biotechnology Institute Novel adjuvant comprising a lipopolysaccharide antagonist
WO2001032697A2 (en) * 1999-11-05 2001-05-10 L'unite De Recherche En Biologie Moleculaire (Urbm) Des Facultes Universitaires Notre Dame De La Paix (Fundp) Virulence genes and proteins from brucella melitensis, and their use
WO2002080964A1 (en) * 2001-04-06 2002-10-17 Institut Pasteur Conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of vibrio cholerae 0139 bound to tetanus toxoid
KR100456681B1 (ko) * 2002-05-22 2004-11-10 주식회사 대웅 박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
EP1996715B1 (de) * 2005-11-23 2012-04-25 National Research Council Of Canada Bakterielle antigene und deren verwendung
WO2010130896A2 (fr) 2009-05-14 2010-11-18 Sanofi Pasteur Procédé pour adjuver le lipopolysaccharide (lps) des bactéries à gram-négatif
CA2761924C (fr) 2009-05-14 2017-10-31 Sanofi Pasteur Vaccin meningocoque a base de lipooligosaccharide (los) provenant de souches modifiees de neisseria meningitidis d'immunotype l6
EP2620162A1 (de) 2012-01-27 2013-07-31 Life Science Inkubator Enzym-Polymer-Konjugat zur Endotoxin-Detoxifikation
US11052142B2 (en) 2013-06-04 2021-07-06 Petr G. Aparin Modified endotoxic bacteria lipopolysaccharide (variants), combination of modified lipopolysaccharides (variants) and, containing same, a vaccine (variants) and a pharmaceutical composition (variants)
US20160120967A1 (en) 2013-06-04 2016-05-05 Petr Gennadievich Aparin Modified endotoxic bacteria lipopolysaccharide (variants), combination of modified lipopolysaccharides (variants) and, containing same, a vaccine (variants) and a pharmaceutical composition (variants)
US20220010281A1 (en) * 2018-10-29 2022-01-13 Ottawa Hospital Research Institute Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4185090A (en) * 1972-02-02 1980-01-22 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4148877A (en) * 1975-12-29 1979-04-10 Choay S. A. Fraction capable of inducing in vivo a resistance to bacterial infections, process for obtaining said fraction from bacteria and drugs containing said fraction
FR2393065A1 (fr) * 1977-05-31 1978-12-29 Merieux Inst Procede de separation de lipides d'endotoxines bacteriennes et notamment d'endotoxine de bordetella pertussis
US4505899A (en) * 1982-05-26 1985-03-19 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4435386A (en) * 1982-05-26 1984-03-06 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4505900A (en) * 1982-05-26 1985-03-19 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
GR860379B (en) * 1985-02-22 1986-06-11 Akzo Nv Novel disaccharide and trisaccharide derivatives of the lipid a type
US4677194A (en) * 1985-08-09 1987-06-30 Biotech Research Laboratories, Inc. Isolation of an endotoxin inactivator from human plasma

Also Published As

Publication number Publication date
US4929604A (en) 1990-05-29
AU7580787A (en) 1987-12-22
DE3751588T2 (de) 1996-03-21
EP0306496B1 (de) 1995-11-08
US5200184A (en) 1993-04-06
US5013661A (en) 1991-05-07
EP0306496A1 (de) 1989-03-15
DE3751588D1 (de) 1995-12-14
AU610509B2 (en) 1991-05-23
JPH04504349A (ja) 1992-08-06
FI885464A7 (fi) 1988-11-24
FI95599B (fi) 1995-11-15
FI885464A0 (fi) 1988-11-24
WO1987007297A1 (en) 1987-12-03
FI95599C (fi) 1996-02-26

Similar Documents

Publication Publication Date Title
ATE130032T1 (de) Verfahren zum verringern der toxizität von lps und verfahren zum dezoxifizieren eines lps- haltigen flüssigen therapeutischen mittels.
Lingwood et al. Receptor affinity purification of a lipid-binding adhesin from Helicobacter pylori
Melly et al. Ability of monomeric peptidoglycan fragments from Neisseria gonorrhoeae to damage human fallopian-tube mucosa
US4094971A (en) Immunological adjuvant agents active in aqueous solution
US3956481A (en) Hydrosoluble extracts of mycobacteria, their preparation and use
AU8134991A (en) Method for obtaining a vaccine with wide protective range against group b neisseria meningitidis, the resulting vaccine, gammaglobulin and transfer factor
Koga et al. Acute joint inflammation in mice after systemic injection of the cell wall, its peptidoglycan, and chemically defined peptidoglycan subunits from various bacteria
Mouricout et al. Pilus-mediated binding of bovine enterotoxigenic Escherichia coli to calf small intestinal mucins
DE2450355A1 (de) Aus n-acyl-muraminsaeurederivaten gebildete adjuvanzien und diese enthaltende impfstoffe
EP0118831A2 (de) Vakzine für gramnegative Bakterien und Verfahren zur Herstellung derselben
MX9708438A (es) Proteina principal de la membrana externa de moraxella, de alto peso molecular.
Lambden et al. Synthesis of immunogenic oligosaccharide-protein conjugates from the lipopolyasaccharide of Neisseria Gonorrhoeae P9
JPS58126797A (ja) ジサツカライドトリペプチド及びジサツカライドテトラペプチドの製法
Schuster et al. Toxic properties of the cell wall of gram-positive bacteria
AU626049B2 (en) Method for preparing vaccine for dental caries and vaccinal compositions for dental caries used as nasal drop
US4370265A (en) Water soluble agents effective as immunological adjuvants for stimulating in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
Jacobs Immunomodulatory effects of bacterial lipopolysaccharide
AT384032B (de) Verfahren zur herstellung von polydispersen nativen pseudomonas-flagella(h)-antigenen (fag)
US4001395A (en) Hydrosoluble extracts of mycobacteria
US4157278A (en) Immunostimulatory agents
Gamian et al. The occurrence of glycine in bacterial lipopolysaccharides
Murao et al. Isolation and characterization of a novel hen egg white lysozyme inhibitor from Bacillus subtilis I-139
Bräutigam et al. Capsule polysaccharide-protein-peptidoglycan complex in the cell envelope of Rhodobacter capsulatus
Maeda et al. Structural requirement of synthetic N-acetylmuramyl dipeptides for induction of experimental allergic encephalomyelitis in the rat
Rogers et al. Cell walls of Mycobacteria

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee